Trastuzumab has been used to manage both early and metastatic HER2-postive breast cancer and has significantly improved the survival of these patients and become the standard of care, according to Arlene Chan, MB BS, FRACP, MMed, writing in Chinese Clinical Oncology.
Trastuzumab has been used to manage both early and metastatic HER2-postive breast cancer with encouraging results. It has significantly improved the survival of these patients and become the standard of care, according to an editorial by Arlene Chan, MBBS, FRACP, MMed, writing in Chinese Clinical Oncology. However, the cost of 12 months of adjuvant trastuzumab therapy, the standard duration of treatment, as well as the cost associated with indefinite use in a metastatic setting, limits patient access to this life-saving drug.
According to Chan, a study published in the Lancet Oncology that evaluated trastuzumab’s limited availability in China, India, and Russia (which make up 40% of the world’s population) showed that only one-third of HER2-positive breast cancer patients in China had access to trastuzumab. The study also demonstrated equivalence of the biosimilar, CT-P6, with reference trastuzumab in the primary outcome measure of pathological complete response (pCR). In line with the FDA’s guidance on using pCR as an endpoint in high-risk early-stage breast cancer following neoadjuvant therapy to support accelerated drug approval, the use of pCR is an appropriate clinical endpoint to demonstrate equivalence of the 2 molecules, said Chan.
With respect to safety, incidence of treatment emergent adverse events appeared to be balanced between the 2 agents. The administration of concurrent anti-HER2 agent with the anthracycline component of neoadjuvant treatment did not show differences in rates of symptomatic cardiac dysfunction, though cardiac function follow-up was only reported until the end of the neoadjuvant phase of treatment. Investigators will also perform a follow-up for disease events for a minimum of 3 years from the enrollment of the last patient to ensure that the equivalent efficacy is maintained.
According to Chan, the real benefit of the study will be determining whether the presumed lower drug costs of the biosimilar translate into greater utilization of this targeted therapy, especially for those who do not currently receive this treatment. The healthcare community is waiting to see whether increasing availability of trastuzumab biosimilar agents will change clinical practice as the financial barriers are lowered.
It will also be important, says Chan, to measure certain outcomes as more biosimilars enter the clinical setting for breast cancer and HER2-positive solid tumors. These outcomes will include institutional and national data collection to show that more patients are receiving this therapy, as well as cost savings that are presumed for health care providers.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.